Muscular dystrophy is not one disease but a family of more than thirty inherited conditions that cause muscles to weaken and waste away over time. Each type traces back to a fault in one of the genes the body needs to build and maintain healthy muscle, and the forms differ widely in which muscles they hit, how quickly they progress, and when symptoms first appear. Some begin in early childhood and advance steadily, while others surface in adulthood and move slowly. This guide explains what muscular dystrophy is, the main types, the symptoms families notice first, how genetic and blood tests confirm the diagnosis, the treatments available today including recently approved gene therapies, and the research changing what the future looks like.
What is muscular dystrophy?
Muscular dystrophy is a group of genetic muscle diseases marked by progressive weakness and loss of muscle mass. In the most common and severe childhood form, Duchenne muscular dystrophy, mutations in the DMD gene leave the body unable to make dystrophin, a protein that acts like a shock absorber to protect muscle fibers during contraction. Without enough working dystrophin, muscle fibers are damaged with ordinary use and are gradually replaced by scar tissue and fat, so strength declines over the years.
The different types vary in cause and course, but they share the theme of a missing or faulty muscle protein. Duchenne and Becker muscular dystrophy together affect roughly 1 in 3,500 to 5,000 newborn boys worldwide, while other forms such as myotonic dystrophy are more common in adults. There is no cure yet, but coordinated care has steadily improved both quality of life and survival, and for Duchenne muscular dystrophy in particular, life expectancy has risen from the teens and twenties toward the thirties and beyond.
Types of muscular dystrophy
Knowing which type is involved shapes everything from expected symptoms to treatment eligibility. The most common forms are summarized below.
| Type | Typical onset | Key features |
|---|---|---|
| Duchenne | Early childhood, before age 5 | The most common and severe childhood form; affects mainly boys; enlarged calves and frequent falls |
| Becker | Teens to thirties | Same gene as Duchenne but milder, because some working dystrophin remains |
| Myotonic | Adulthood most often | The most common adult form; muscle stiffness plus cataracts and heart rhythm problems |
| Limb-girdle | Childhood to adulthood | Weakness centered on the hip and shoulder muscles |
| Facioscapulohumeral | Teens to young adulthood | Often uneven weakness of the face, shoulders, and upper arms |
| Emery-Dreifuss | Childhood to early adulthood | Early joint contractures and serious heart conduction problems |
| Congenital | At birth or before age 2 | Present very early with a wide range of severity |
Symptoms of muscular dystrophy
Symptoms depend heavily on the type, but progressive muscle weakness is the common thread. In Duchenne muscular dystrophy, parents often notice a young boy who is late to walk, falls frequently, struggles to run or climb stairs, and walks with a waddling gait. A classic sign is using the hands to “walk up” the thighs when rising from the floor, and the calf muscles may look enlarged even as they weaken, because muscle is being replaced by other tissue.
As muscular dystrophy advances, weakness spreads and contractures can develop, where muscles and tendons tighten and limit joint movement. Several types also affect the heart and breathing muscles, leading to cardiomyopathy or reduced lung capacity, which is why heart and respiratory monitoring is a core part of care. Myotonic dystrophy adds its own signature symptom, difficulty relaxing a muscle after using it, along with cataracts and heart rhythm changes. Because some forms strain the heart, families often learn to watch for the symptoms of the weakened pumping described in heart failure.
What causes muscular dystrophy?
Muscular dystrophy is caused by mutations in genes responsible for building muscle proteins, most famously the gene that makes dystrophin. Different types follow different inheritance patterns. Duchenne and Becker muscular dystrophy are X-linked recessive, so they mainly affect boys, who have a single X chromosome; girls can be carriers and occasionally have symptoms. Other forms can be autosomal dominant, meaning one altered copy is enough to cause disease, or autosomal recessive, requiring two altered copies.
Because the conditions are genetic, they are present from birth even when symptoms take years to appear, and they are not caught from another person or caused by activity or diet. In a portion of cases there is no family history, because a new mutation arises spontaneously. For families affected by an X-linked form, carrier testing of female relatives can clarify the chance of passing the condition on and inform family planning.
How muscular dystrophy is diagnosed
Diagnosis usually begins with a simple blood test. When muscle fibers break down, they release an enzyme called creatine kinase into the bloodstream, and levels are strikingly high in several muscular dystrophies, especially Duchenne, where they can run ten to twenty times above the normal range early in life. A markedly elevated result is a strong clue that points toward a muscle disease and prompts confirmatory testing. You can read more about what this enzyme reflects in this overview of the creatine kinase levels measured by a CPK blood test.
Genetic testing then confirms the diagnosis and identifies the exact mutation, which matters because several newer treatments only work for specific genetic changes. Doctors first look for missing or duplicated sections of the gene, which account for most Duchenne cases, and use broader sequencing to find smaller mutations. A muscle biopsy is now needed less often but can measure dystrophin directly in unclear cases, and electromyography can help separate a muscle disorder from a nerve problem. Because the heart and lungs are frequently involved, the workup also includes an electrocardiogram, an echocardiogram, and breathing tests. Understanding how to read the flags and reference ranges on a lab report can help families follow what these numbers mean over time.
Treatment options for muscular dystrophy
There is no cure for muscular dystrophy yet, but treatment can slow progression, ease symptoms, and prevent complications, and the options have expanded quickly in recent years. Care is delivered by a multidisciplinary team and tailored to the type and stage of disease.
| Approach | Examples | Role |
|---|---|---|
| Corticosteroids | Prednisone, deflazacort | Long-standing standard in Duchenne to preserve strength, with side effects to manage |
| Steroid alternative | Vamorolone | Aims for similar benefit with less impact on growth and bone |
| Exon-skipping drugs | Eteplirsen, golodirsen, viltolarsen, casimersen | Help certain Duchenne mutations make a partial dystrophin protein |
| Gene therapy | Delandistrogene moxeparvovec | A one-time infusion delivering a shortened dystrophin gene to muscle |
| Nonsteroidal medicine | Givinostat | An oral drug for Duchenne across genetic subtypes |
| Supportive care | Physical therapy, braces, heart and lung care | Maintains mobility and manages complications across all types |
Corticosteroids remain a cornerstone for Duchenne muscular dystrophy because they help preserve muscle strength and delay loss of walking, though long-term use brings weight gain, slowed growth, and bone thinning that need careful management. Vamorolone was developed as an alternative that aims to keep the benefits while reducing some of those side effects. Mutation-specific exon-skipping drugs and, more recently, a one-time gene therapy work at the genetic level to restore some dystrophin, while the oral drug givinostat offers a nonsteroidal option across genetic subtypes. Alongside these, physical and occupational therapy, bracing, assistive devices, and proactive heart and respiratory care remain essential for every type.
Living with muscular dystrophy and long-term outlook
The course of muscular dystrophy depends on the type, but proactive, coordinated care has changed what living with it looks like. Regular monitoring of the heart and lungs allows problems to be treated early, physical therapy and bracing help preserve movement and prevent contractures, and mobility aids support independence as the disease advances. Nutrition, bone health, and emotional support all matter over the long run.
For Duchenne muscular dystrophy, the combination of corticosteroids, cardiac and respiratory support, and newer therapies has extended survival well beyond what was typical a generation ago, with many people now living into adulthood. Slower-progressing forms such as Becker and some limb-girdle types may have a smaller effect on lifespan. Because the heart is so often involved, ongoing cardiac care is one of the most important parts of a long-term plan.
Latest scientific advances in muscular dystrophy research
Muscular dystrophy research is moving fast, with the biggest gains in therapies that address the genetic root of Duchenne. According to PubMed-indexed research, a 2026 report in Neurology and Therapy presented two-year outcomes from the EMBARK trial of the gene therapy delandistrogene moxeparvovec, finding that treated boys did significantly better than a matched comparison group on measures tied to walking and rising from the floor, even though the trial’s one-year primary goal had not reached statistical significance (Mendell et al., 2026). What this means for you: longer follow-up strengthens the case that gene therapy can slow decline in young, still-walking boys, while underlining that benefits unfold gradually and expectations should be realistic.
A 2026 analysis in Neurology compared vamorolone with traditional corticosteroids and found similar gains in motor function while protecting the linear growth that prednisone and deflazacort tend to suppress (Clemens et al., 2026). What this means for you: for families worried about steroid side effects in a growing child, this supports vamorolone as a legitimate alternative, though weight gain can still occur. Looking further ahead, a 2025 phase 1/2 trial in Cell Reports Medicine tested a next-generation exon-skipping drug called brogidirsen and reported dystrophin restoration far above what first-generation drugs achieve, reaching about a quarter of normal levels in a small group (Komaki et al., 2025). What this means for you: more potent genetic therapies in the pipeline could eventually deliver larger benefits for people with eligible mutations.
Glossary of key muscular dystrophy terms
| Term | Definition |
|---|---|
| Dystrophin | A protein that protects muscle fibers during contraction; missing in Duchenne. |
| Creatine kinase | A muscle enzyme that leaks into the blood when muscle is damaged. |
| X-linked recessive | An inheritance pattern that mainly affects boys, seen in Duchenne and Becker. |
| Contracture | Tightening of a muscle or tendon that limits joint movement. |
| Cardiomyopathy | Disease of the heart muscle, a common complication of several types. |
| Exon skipping | A drug strategy that helps certain mutations produce partial dystrophin. |
| Gene therapy | A treatment that delivers a working or shortened gene into the body’s cells. |
Frequently asked questions about muscular dystrophy
What is muscular dystrophy and what causes it?
Muscular dystrophy is a group of inherited diseases that cause progressive muscle weakness and wasting. Each type is caused by a mutation in a gene needed to build or maintain muscle, most famously the gene for a protein called dystrophin. Because it is genetic, it is present from birth and is not contagious.
What are the early signs and symptoms of muscular dystrophy?
Early signs depend on the type. In Duchenne muscular dystrophy, families often notice a young boy who falls often, has trouble running or climbing stairs, walks on his toes or with a waddle, and uses his hands to push up his legs when standing. Other forms may first appear as weakness in the face and shoulders or as muscle stiffness in adulthood.
Is Duchenne muscular dystrophy inherited as dominant or recessive?
Duchenne and Becker muscular dystrophy are X-linked recessive, so they mainly affect boys, who have one X chromosome. Girls can be carriers and sometimes have milder symptoms. Other types of muscular dystrophy can be autosomal dominant or autosomal recessive.
How is muscular dystrophy diagnosed, and what does a high creatine kinase mean?
Diagnosis usually starts with a creatine kinase blood test, which is often very high because damaged muscle releases the enzyme into the blood. A markedly elevated level points toward a muscle disease and leads to genetic testing that confirms the diagnosis and pinpoints the exact mutation, sometimes supported by a muscle biopsy or nerve and muscle studies.
What is the life expectancy for someone with Duchenne muscular dystrophy today?
With modern care, including corticosteroids and proactive heart and lung support, many people with Duchenne muscular dystrophy now live into their thirties or beyond, a marked improvement over past decades. Milder forms such as Becker may have little effect on lifespan.
Is there a cure for muscular dystrophy?
There is no cure yet, but treatments can slow progression and manage complications, and options have grown to include steroid alternatives, exon-skipping drugs, a one-time gene therapy, and a nonsteroidal oral medicine for Duchenne. Research into more powerful genetic therapies is ongoing.
Sources
- Centers for Disease Control and Prevention — Muscular Dystrophy Types — CDC, 2024 — cdc.gov
- Mayo Clinic Staff — Muscular Dystrophy: Symptoms and Causes — Mayo Clinic Diseases & Conditions, 2024 — mayoclinic.org
- MedlinePlus, National Library of Medicine — Duchenne and Becker Muscular Dystrophy — MedlinePlus Genetics, 2024 — medlineplus.gov
- Mendell JR, Muntoni F, McDonald CM, et al. — Two-Year Outcomes Following Delandistrogene Moxeparvovec Treatment in Ambulatory Patients with Duchenne Muscular Dystrophy: Phase 3 EMBARK Trial — Neurology and Therapy, 2026 — doi.org/10.1007/s40120-025-00879-8
- Clemens PR, Berglund EA, Schiava M, et al. — Vamorolone for Duchenne Muscular Dystrophy: A Cross-Trial Efficacy Comparison With Classic Corticosteroids — Neurology, 2026 — doi.org/10.1212/WNL.0000000000214756
- Komaki H, Takeshita E, Kunitake K, et al. — Phase 1/2 Trial of Brogidirsen: Dual-Targeting Antisense Oligonucleotides for Exon 44 Skipping in Duchenne Muscular Dystrophy — Cell Reports Medicine, 2025 — doi.org/10.1016/j.xcrm.2024.101901
Further reading
- See what a muscle-damage enzyme reveals by reading this guide to the creatine kinase levels on a CPK test.
- Understand a heart complication that several types can cause in this guide to the weakened pumping of heart failure.
- Compare muscular dystrophy with another progressive muscle-and-nerve disease in this guide to the motor neuron loss of Lou Gehrig’s disease.
- Explore a different cause of childhood movement difficulty in this guide to the movement disorder of cerebral palsy.
- Build confidence reading test results with this guide to reference ranges, flags, and next steps on a lab report.
Understand your lab results with BloodSense
Muscular dystrophy shows how a single blood marker can open the door to a diagnosis, since a strikingly high creatine kinase is often the first clue that leads to genetic testing. Whenever you receive lab results, seeing how each value compares with its reference range, and how the numbers fit together over time, makes them far easier to act on. BloodSense translates a full lab report into plain language, showing where each marker sits and helping you follow changes across visits instead of interpreting one line at a time.
